UBS raises c3.ai stock price target to $17 on cautious outlook

C3.ai (NYSE:AI) is experiencing significant investor caution, with its stock down over 52% year-to-date and trading near its 52-week low. Multiple analysts have recently reduced price targets, including UBS to $16 and KeyBanc to $10, citing concerns over limited growth visibility, execution failures on large deals, and potential disruption from the new CEO's unfinalized overhaul plan. These challenges, compounded by leadership transitions and CEO health issues, temper the impact of recent product launches and strategic partnerships, contributing to a cautious outlook for the AI software provider.

Analysis

C3.ai (NYSE:AI) is facing significant headwinds, evidenced by its stock trading near its 52-week low after a more than 52% year-to-date decline. Despite a minor price target increase by UBS to $17.00, the firm maintained a Neutral rating, citing limited visibility into fiscal year 2027 growth prospects. This sentiment is amplified by more bearish actions from other analysts, including a target reduction to $16 by Canaccord Genuity and a slash to $10 by KeyBanc, which attributes its pessimism to leadership changes and executive health issues. The company's recent first-quarter weakness was pinned on internal "execution failures" with large deals, not a broad-based demand issue, which points to significant operational challenges. A major overhang is the lack of a finalized overhaul plan from the new CEO, which UBS notes could cause "significant disruption" for several quarters. While C3.ai's fiscal 2026 revenue framework of $290-300 million is seen as conservative, the multiple uncertainties have kept UBS from adjusting its $299 million estimate. Positive catalysts, such as the launch of the C3 AI Agentic Process Automation platform and a strategic partnership with SMX, are currently overshadowed by these fundamental concerns about execution, leadership stability, and future growth.

Key Decisions for Investors

• Investors should treat C3.ai with significant caution, as the deeply depressed stock price is a reflection of severe operational and leadership uncertainties, making any potential entry contingent on tangible evidence of improved deal execution and clarity on the new CEO's strategic plan.
• Current shareholders should re-evaluate their thesis, as the combination of execution failures, a pending management overhaul, and multiple analyst target reductions signals a heightened risk profile for the medium term.
• The extremely wide analyst price target range of $8 to $25 highlights a profound lack of consensus and suggests investors should anticipate high volatility, with the stock's performance likely to be driven by news flow on management's strategy rather than underlying fundamentals in the coming quarters.